Guillain-Barre Syndrome After Astrazeneca Covid-19-Vaccination: A Causal Or Casual Association?
CLINICAL NEUROLOGY AND NEUROSURGERY(2021)
摘要
We report a case of Guillain-Barre ' syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies.
更多查看译文
关键词
COVID-19, Vaccine, AstraZeneca, Guillain-Barre syndrome
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要